Amylyx announces conference call on AMX0035 Phase 3 PSP trial; no new data

Amylyx Pharmaceuticals, Inc.

Hosted investor call on July 26, 2023 to discuss PSP and Orion Phase 3 trial of AMX0035.
No clinical results or data disclosed; only trial design and scientific rationale overview.
Presenters included co-CEOs, clinical development head, and external investigator Prof. Höglinger.
Attached slides outline rationale and design, not outcomes or milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.